Publications by authors named "Adam Petrich"

Claim this Profile
A
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Adam Petrich

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Yasong Lu, Shuang Liang, Ying Hong, Naoyuki Tajima, Kashyap Patel, Adam Petrich

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
Reem Karmali, Jeremy S Abramson, Deborah M Stephens, Jeffrey Barnes, Jane N Winter, Adam M Petrich

Blood Adv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Adam M Petrich

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Junichiro Yuda, Christine Will, Darren C Phillips, Linu Abraham, Cory Alvey, Adam Petrich

Commun Med (Lond)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
Patricia LoRusso, Mark J Ratain, Toshihiko Doi, Drew W Rasco, Maja J A de Jonge, Adam Petrich

Invest New Drugs· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Ajay Major, Justin Kline, Theodore G Karrison, Paul A S Fishkin, Amy S Kimball, Adam M Petrich

Haematologica· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
William B Pearse, Adam M Petrich, Leo I Gordon, Reem Karmali, Jane N Winter

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Pier Luigi Zinzani, Ian W Flinn, Sam L S Yuen, Max S Topp, Chiara Rusconi, Adam Petrich

Blood· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Andrew D Zelenetz, Gilles Salles, Kylie D Mason, Carla Casulo, Steven Le Gouill, Adam M Petrich

Blood· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Natalie Galanina, Sonali M Smith, Chuanhong Liao, Adam Petrich, Bernadette Libao

Br J Haematol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Mary-Kate Malecek, Adam M Petrich, Shaina Rozell, Benjamin Chu, Steven Trifilio

Am J Hematol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Jennifer A Regan, Yun Cao, Melanie C Dispenza, Shuo Ma, Leo I Gordon, Adam M Petrich

J Allergy Clin Immunol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, Kristie A Blum, Christina Howlett, Adam M Petrich

J Clin Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Reem Karmali, Chadi Nabhan, Adam M Petrich, Jeffrey Raizer, David Peace

Br J Haematol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Daniel J Landsburg, Marissa K Falkiewicz, Adam M Petrich, Benjamin A Chu, Amir Behdad

Br J Haematol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
Adam Petrich, Chadi Nabhan

Leuk Lymphoma· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving role of lenalidomide in non-Hodgkin lymphoma.
Natalie Galanina, Adam Petrich, Chadi Nabhan

Leuk Lymphoma· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
M Estela Martinez-Escala, Timothy M Kuzel, Jason B Kaplan, Adam Petrich, Beatrice Nardone

JAMA Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Daniel J Landsburg, Adam M Petrich, Jeremy S Abramson, Aliyah R Sohani, Oliver Press

Cancer· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
Andrew M Evens, Jennifer A Kanakry, Laurie H Sehn, Athena Kritharis, Tatyana Feldman, Adam M Petrich

Am J Hematol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era.
Adam M Petrich, Irene B Helenowski, Locke J Bryan, Shaina A Rozell, Robert Galamaga

Br J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Adam M Petrich, Chadi Nabhan, Sonali M Smith

Cancer· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J Castillo, Saurabh Rajguru

Blood· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Mitul D Gandhi, Andrew M Evens, Timothy S Fenske, Paul Hamlin, Bertrand Coiffier, Adam M Petrich

Blood· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis